Kornimate/medical-research-clean huggingface dataset:
prescription pattern and awareness about antibiotic prophylaxis and resistance

Conditions: Antibiotic Prescription

Summary: to assess the knowledge of pediatric dentists regarding the prescription of antibiotics, antibiotic prophylaxis and antibiotic resistance

antibiotics commonly are prescribed by dentists, and the uses and abuses of these drugs should be familiar to all practicing clinicians. antibiotics are used in dentistry for two major reasons: to control oral infection, and to prevent a bacteremia precipitated by dental manipulations from causing severe systemic sequelae. in recent years, there has been an increasing tendency to reduce the widespread use of antibiotics for prophylactic and therapeutic purposes. this is based, both on increasing scientific evidence and enhanced professional experience. the development of resistant strains of microorganisms, doubt on the efficacy of the proposed prophylactic regimens, possible toxic and adverse reactions to antibiotics and poor compliance by patients and dentists raised questions about risks and benefits. the american academy of pediatric dentistry (aapd) has published guidelines for antibiotic use, recognizing the increasing prevalence of antibiotic-resistant microorganisms. the guidelines are intended to provide guidance for the proper and judicious use of antibiotic therapy in the treatment of oral conditions in children. good knowledge about the indications of antibiotics is the need of the hour in prescribing antibiotics for dental conditions. dental practitioners should know the protocol to be applied in their patients and should apply the most recent guidelines regarding antibiotic regimen.

Eligibility criteria:
* inclusion criteria: * dental practitioner * deal with children * exclusion criteria: * undergraduate student

Keywords: prescription pattern antibiotic prophylaxis antibiotic resistance
a study of guselkumab in adult participants with celiac disease

Conditions: Celiac Disease

Summary: the purpose of this study is to evaluate the safety and tolerability of guselkumab compared to placebo in participants with celiac disease.


Eligibility criteria:
inclusion criteria: * have a body mass index (bmi) 16 to 45 kilogram per meter square (kg/m\^2). underweight participants (bmi 16 to 18 kg/m\^2) may only be included if in the opinion of the investigator a participant was underweight due to active celiac disease and thus, may benefit from therapy but yet not be at significantly increased risk due to severe malabsorption or other conditions * physician-diagnosed celiac disease with documented history of biopsy-proven celiac disease * self-reported to be on a gluten-free diet (gfd) for at least 11 consecutive months prior to enrollment and have the willingness to continue to adhere to the same gfd while on study * willing to take/ingest gluten-containing product at specific study timepoints only (if assigned to module b) * willing to undergo up to 3 on-study esophagogastroduodenoscopy (egd) with biopsies exclusion criteria: * has a history of chronic inflammatory gastrointestinal disease (example, inflammatory bowel disease, extensive colitis, ulcerative jejunitis, eosinophilic esophagitis) * has chronic infectious gastrointestinal illness, or acute infectious gastrointestinal illness within the 4-week period prior to screening * currently has a malignancy or a history of malignancy within 5 years before screening (with the exception of a non-melanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study intervention administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study intervention); known history of lymphoproliferative disease, including monoclonal gammopathy of unknown significance, lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly * has a history of, or ongoing, chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection, recurrent urinary tract infection (example, recurrent pyelonephritis or chronic non-remitting cystitis), or open, draining, or infected skin wounds or ulcers * has had previous treatment with guselkumab
bripped scan for evaluation of emergency department (ed) patients with shortness of breath

Conditions: Dyspnea

Summary: the b-ripped scan is a standardized ultrasound evaluation of pulmonary b-lines, right ventricle size and strain, inferior vena cava collapsibility, pleural and pericardial effusion, pneumothorax, ejection fraction, and lower extremity deep venous thrombosis. primary outcomes measured are the magnitude of change in differential diagnoses.

this prospective randomized control trial will be performed on a convenience sample of 200 patients presenting with undifferentiated sob to an academic emergency department (ed) (volume 56,000 patients/year). subjects are excluded if they have a known history of asthma, are 20 or more weeks pregnant, or have had thoraco-abdominal trauma in the past 72 hours. the bripped pilot investigation (irb #10-02-fb-0026) enrolled 43 patients and physician subjects from 4/30/2010 to 1/20/2011. this study differs in methodology from the pilot study in the reduction of the total number of ultrasound images obtained to decrease the total time to perform the scan. instead of a cohort study, this randomized control trial includes the addition of a control group for cost and time saved comparison. as in the pilot study, eligible patients will be evaluated by the treating ed physician who will rank potential diagnoses from most to least likely. a study investigator performs the b-ripped scan and provides the initial treating physician with the results. the treating physician will again be asked to complete a differential diagnosis ranking knowing the b-ripped results. changes in the differential diagnosis ranking, physician orders, and interventions will be compiled. a randomized control cohort will be assigned for eligible patients. in the control group, the treating physician will complete the diagnosis rank list prior to the completion of the workup, and then once all lab values are back. time to disposition, and comparison of labs and radiology tests ordered will be compared to the cohort receiving the bripped scan. patients will be assigned a number at time of enrollment, which randomly assigns them to the control or experimental (patients receiving the bripped scan) group. packets containing the appropriate data collection form (control or experimental) will be organized so even numbered patients will belong to one group, and odd numbered patients will be assigned to the other.

Eligibility criteria:
inclusion criteria: subjects are included if they are between the ages of 18-89 and present to the emergency department with a chief complaint of shortness of breath or dyspnea. exclusion criteria: * known history of asthma, * are 20 or more weeks pregnant, or * have had thoraco-abdominal trauma in the past 72 hours.

Keywords: dyspnea ultrasonography emergencies critical care
conditions of diagnostic panendoscopy of the upper airway under propofol remifentanil general anesthesia

Conditions: Tumor of Ear, Nose and Throat

Summary: the most important considerations for the general anesthesia in diagnostic panendoscopy of the upper airway is the maintenance of a patient's airway for optimal surgical exposure, adequate ventilation and sufficient depth of anesthesia. tubeless anesthestic techniques with preserved spontaneous ventilation and total intravenous administration of anesthetic drugs are widely use. due to its pharmacological profile, propofol anesthesia is often considered as the gold standard for the anesthesia in the diagnostic panendoscopy. previous studies suggested that adding remifentanil to propofol could improve the conditions for laryngoscopy and tracheal intubation. the aim of this study is to assess the impact of propofol remifentanil general anesthesia compared to propofol general anesthesia on the conditions of the diagnostic panendoscopy of the upper airway.


Eligibility criteria:
inclusion criteria: * elective diagnostic panendoscopy of the upper airway * age \> 18 and \< 80 years old * american society of anesthesiology (asa) score equal to 1, 2, or 3 with a stable condition * written inform consent exclusion criteria: * pregnancy or breastfeeding * age \< 18 years old or inability to give informed consent * known anaphylaxis to remifentanil or propofol * long term opioid use, drug abuse * predictive criterion of impossible mask ventilation or intubation * chronic respiratory failure requiring oxygen therapy

Keywords: diagnostic panendoscopy of the upper airway total intravenous general anesthesia remifentanil propofol target controlled infusion direct laryngoscopy tracheoscopy oesophagoscopy ear nose and throat (ent) tumor ear nose and throat (ent) cancer
six-month study to compare the effects of volume- and pressure-guided adjustments on weight loss and satiety

Conditions: Morbid Obesity

Summary: the purpose of this protocol is to determine how band fill volumes that are based on intraband pressure readings can influence the comfortability of the band and to compare weight loss with this methodology to weight loss with the conventional approach recommended in existing product labeling.


Eligibility criteria:
inclusion criteria: * able to comprehend, follow and give informed consent. * be at least 18 years of age at time of trial enrollment. * had a pre-implantation bmi between 35 and 55 kg/m2. * have received a sagb vc implant 1) 30-60 days (and not undergone first band adjustment yet)prior to the date of enrollment. * willingness to be randomized to intraband-based or conventional adjustments * willingness to consent to monthly visits and possible measurements of intraband pressure (requiring access to the injection port). * willingness to undergo up to 7 band adjustments within the 6-month period of the study. * able to sit approximately at a 90 degree-angle, from the floor, for ibp measurements. * willingness to return to office visits around the same time of the first in-study adjustment (plus or minus 2 hours) * willingness to consent to a limited ugi series if the investigator suspects the presence of a band-related complication or if the intraband pressure recordings deviate from expected. * willingness to refrain from taking medications or supplements indicated for or known to induce weight loss. exclusion criteria: * females currently known to be pregnant. * ongoing or unresolved band perforation or band leakage. * ongoing (unresolved) slippage, erosion, or pouch dilation. * documented esophageal dysmotility/dyskinesia. * ongoing (unresolved) port obstruction or tube kinking. * current injection port infection. * history of band revision or replacement. * previously documented or ongoing esophageal dilatation. * any condition that, in the opinion of the investigator, may jeopardize the subject's well-being or the soundness of this study. * current use of medications or supplements indicated for or known to induce weight loss at any point during the study.

Keywords: morbid obesity gastric banding bariatric banding swedish adjustable gastric band
prevention of preterm birth with a pessary in triplet

Conditions: Preterm Birth

Summary: the incidence of multiple gestations has increased over the past years, mostly because of increased use of assisted reproductive technologies. triplet pregnancies are at increased risk of preterm birth (ptb), which is the primary reason for their increased morbidity and mortality compared to singletons. multiple gestations, including triplets, account for about 3% of all pregnancies in the us but constitute at least 10% of cases of ptb, over 30% of very low birth weight infants, and nearly 20% of infant mortality. a short cervical length (cl) on transvaginal ultrasound (tvu) has been shown to be a good predictor of ptb, including in multiple gestations. in singletons with a prior ptb and a short cl \<25mm before 24weeks, cerclage is associated with significant decreases in ptb and perinatal morbidity and mortality in the meta-analysis of randomized trials (rcts). on the contrary, the effect of cerclage in multiple gesttations has been insufficiently studied, with meta-analysis data showing a possible harm from cerclage compared to controls. the aim of this rct is to evaluate the efficacy of cervical pessary in prevention of ptb in unselected triplet gestations. we planned to assess outcomes in subgroup analysis of women with short cervical length (tvu cl \<30 mm)


Eligibility criteria:
inclusion criteria: * 18-50 years of age * triplet pregnancy (limits the participants to female gender) * gestational age at randomization between 20(0) and 22(6) exclusion criteria: * singleton, twin or higher order than triplets multiple gestation * twin twin transfusion syndrome * ruptured membranes * lethal fetal structural anomaly * fetal chromosomal abnormality * cerclage in place (or planned placement) * vaginal bleeding * suspicion of chorioamnionitis * ballooning of membranes outside the cervix into the vagina * painful regular uterine contractions * labor * placenta previa
mobile and remote monitoring of seating pressure for wheelchair users with sci

Conditions: Spinal Cord Injuries

Summary: this study will examine two interventions to increase weight shifts, overall trunk movement, and self-efficacy related to pressure ulcer prevention in wheelchair users with a spinal cord injury (sci).

participants will use a mobile seat interface pressure mapping system that gives them live, real-time, visual feedback on the distribution of pressure between them and their seat cushion. this type of feedback works as a compensatory strategy for lack of sensation and allows the individual to visually observe pressure distribution they are not able to feel. additionally, the participants will be provided with structured pressure ulcer prevention education, grounded in the principles of social cognitive theory, regarding pressure ulcer risk and use of weight shifts. the pressure mapping system, which will be used during training, provides virtual modeling of the desired outcome (reduced pressure) and is an important part of the education module. the findings of this study will inform clinicians and investigators of whether use of mobile seat interface pressure mapping as a compensatory-based intervention has a positive impact on trunk movement and self-efficacy for completing weight shifts in wheelchair users who lack sensation. another contribution of this work is an exploration of the relationship between self-efficacy and movement in wheelchair users.

Eligibility criteria:
inclusion criteria: * individuals with a spinal cord injury (c4 and below, traumatic or non-traumatic, with onset greater than 12 months at enrollment) * individuals who use a wheelchair as their primary form of mobility * individuals who are willing to participate and able to make 2 visits to the mayo clinic in rochester, mn exclusion criteria: * documented active pressure ulcer of any stage at initiation of study

Keywords: spinal cord injury seating pressure mapping pressure injury prevention seating interface pressure wheelchair user
prevention of contrast induced nephropathy (nic) by intravenous versus oral rehydration

Conditions: KIDNEY FAILURE, ACUTE

Summary: the purpose of this study is to compare the efficacy of oral versus intravenous hydration in the prevention of the contrast-induced nephropathy.

objective: to compare the efficacy of oral versus intravenous hydration in the prevention of the contrast-induced nephropathy (cin) in inpatients with different renal function and equal type and volume of contrast. methods: the clinical trial will include 324 patients with gfr higher or equal to 30 ml/min who will receive intravenous contrast (iohexol: 300 mg of l/ml; approximate volume: 120 ml at 2-5ml/second) in the following 12-24 hours. patients with inclusion criteria, and having previously signed a consent form, will be randomised into 3 groups (intravenous hydration, oral and no hydration). intravenous hydration will be carried out with bicarbonate 1/6m one hour before the test (3ml/kg/h) and oral hydration with casen solution in will be carried out 4 hours before (75 ml/10 kg) the intravenous contrast administration. in relation to the hydrated, it should be pointed out that, the same procedure would have been carried out without the study. the follow-up of renal function will be carried out after measuring creatinine and cystatin c in blood and gfr pre- and 24 hour after the test. it will also determine neutrophil gelatinase-associated lipocalin (n-gal), il-8 and f2-isoprostanes levels in urine and superoxide dismutase activity in erythrocytes, pre- and in different post- test times. also, in vitro, the effect of contrast on nadph-oxidase activity of pbls isolated from 30 control patients will also be studied (10 patients by each group).

Eligibility criteria:
inclusion criteria: * hospitalized patients * aged less than 18 years * provision for the performance of iv contrast (120-150 ml) within 12-24 h. exclusion criteria: * nephropathy patients with stage 4-5 according to the classification of chronic kidney disease (ckd) of the u.s. national kidney foundation's kidney disease outcome quality initiative (nkf-kdoqi). the gfr is estimated by the formula modification diet renal diseases study (mdrd). * patients undergoing: cardiac catheterization or other proceeding in contrast with the previous week, colonoscopy in 48 hours or have received prior nephrotoxic (aminoglycosides and / or certain chemotherapeutic agents) 24-48 hours before the test or in hours.

Keywords: contrast nephropathy renal failure
personalized therapy study - attain stability quad post-approval study

Conditions: Heart Failure

Summary: the purpose of this post-approval study (pas) is to evaluate the long-term performance of the model 4798 left ventricular (lv) lead in a real-world patient population. patients will be followed for the duration of the pas. this study is required by fda as a condition of approval of the model 4798 lv lead and is integrated within the product surveillance registry (psr).

the attain stability quad (asq) pas is a multi-center, single arm, prospective observational study. however, in the us, retrospective enrollments from participants in the ide study (ide #g170020) are allowed.

Eligibility criteria:
inclusion criteria: * patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements * patient has or is intended to receive or be treated with a model 4798 lead and a medtronic crt device * patient within 30 days of therapy received at the time of their initial psr platform enrollment exclusion criteria: * patient who is, or is expected to be inaccessible for follow-up * patient with exclusion criteria required by local law * patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results
safety study of human myeloid progenitor cells (clt-008) after chemotherapy for leukemia

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Myelodysplasia

Summary: ex vivo expanded human myeloid progenitor cells (hmpcs; clt-008) have the potential to accelerate neutrophil recovery and decrease the risk of febrile neutropenia and infection in patients receiving chemotherapy for acute lymphoblastic leukemia (all), acute myeloid leukemia (aml), chronic myeloid leukemia (cml), or high-risk myelodysplasia (mds). in this study, the safety, tolerability and activity of clt-008 administered after "standard of care" cytarabine-based consolidation or induction/re-induction chemotherapy will be determined by monitoring for adverse reactions, infusion reactions, graft-versus host disease (gvhd), neutrophil and platelet recovery, hmpc persistence, infections and complications.


Eligibility criteria:
key inclusion criteria: * hematological malignancy, including: * aml, all or mds * planned treatment with cytarabine-based chemotherapy regimen * adequate hepatic, renal, hematologic, cardiac and respiratory function key exclusion criteria: * prior allograft or history of active gvhd within 3 years * pregnant or nursing

Keywords: induction chemotherapy re-induction chemotherapy consolidation chemotherapy leukemia myelodysplasia
photodynamic therapy incubation times for actinic keratosis

Conditions: Actinic Keratoses

Summary: this is a randomized clinical trial evaluating blue light 5-aminolevulinic acid (ala) photodynamic therapy with different incubation times for the treatment of actinic keratosis. subjects who are interested in participating, currently living in the chicago metropolitan area, and meet inclusion and exclusion criteria will be enrolled in the study. subjects will be randomized to either 1) zero time ala incubation or 2) 1 hour ala incubation. demographic and health data will be collected prior to treatment initiation. three visits will be conducted: screening, treatment, and follow up visit at 8 weeks. this study is a pilot study designed to determine feasibility of this procedure.


Eligibility criteria:
inclusion criteria: 1. subjects who have been diagnosed with actinic keratosis. 2. subjects who by the investigator deem to be suitable for photodynamic therapy of the face or scalp. 3. males or females ≥ 18 years old 4. fitzpatrick skin types i-vi 5. subjects are in good health as judged by the investigator. 6. subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator. exclusion criteria: 1. subjects who by the investigator are not suitable for photodynamic therapy. 2. lesions suspicious or proven for skin cancer 3. history of 2 or more ala- pdt treatments within the past 6 months. 4. use of keratolytics within 2 days of initiation of treatment (e.g., \>5% urea, glycolic acid, lactic acid, salicyclic acid) 5. cryotherapy within the past 2 weeks. 6. topical retinoids within the past 4 weeks 7. procedures, such as microdermabrasion, ablative lasers, ala-pdt, chemical peels, 5-fluorouraci, diclofenac, imiquimod within the past 8 weeks 8. systemic retinoids within the past 6 months 9. pregnant or breast feeding 10. uncooperative subjects or subjects with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations. 11. subjects who are unable to understand the protocol or give informed consent. 12. subjects who in the opinion of the investigator are not suitable for the study.